Contact
searchSearch
HMP Global
Login

Breast Cancer Excellence Forum

Breast Cancer
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Lajos Pusztai, MD, DPhil
Videos
T-DXd Improves Residual Cancer Burden in HER2-Positive Early Breast Cancer
05/19/2026
Lajos Pusztai, MD, DPhil
Lajos Pusztai, MD, DPhil, discusses post hoc analysis results from the of the phase 3 DESTINY-Breast11 trial assessing neoadjuvant T-DXd plus paclitaxel, trastuzumab, and pertuzumab in HER2-positive early breast cancer.
Lajos Pusztai, MD, DPhil, discusses post hoc analysis results from the of the phase 3 DESTINY-Breast11 trial assessing neoadjuvant T-DXd plus paclitaxel, trastuzumab, and pertuzumab in HER2-positive early breast cancer.
Lajos Pusztai, MD, DPhil,...
05/19/2026
Oncology
Sara Hurvitz, MD
Videos
PI3K Pathway Inhibition Improves Outcomes in Patients With Advanced Breast Cancer
05/08/2026
Sara Hurvitz, MD
Sara Hurvitz, MD, discusses results from the phase 3 VIKTORIA-1 trial evaluating gedatolisib-based combinations in previously treated HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer.
Sara Hurvitz, MD, discusses results from the phase 3 VIKTORIA-1 trial evaluating gedatolisib-based combinations in previously treated HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer.
Sara Hurvitz, MD, discusses...
05/08/2026
Oncology
Paolo Tarantino, MD
Videos
Sacituzumab Govitecan Demonstrates Limited Activity Following T-DXd in HER2-Positive Metastatic Breast Cancer
05/07/2026
Paolo Tarantino, MD, PhD
Paolo Tarantino, MD, discusses results from the phase 2 SATEEN trial evaluating sacituzumab govitecan plus trastuzumab in heavily pretreated patients with HER2-positive metastatic breast cancer.
Paolo Tarantino, MD, discusses results from the phase 2 SATEEN trial evaluating sacituzumab govitecan plus trastuzumab in heavily pretreated patients with HER2-positive metastatic breast cancer.
Paolo Tarantino, MD, discusses...
05/07/2026
Oncology
Sarah Premji, MD
Videos
Clinical Differences Among Oral SERDs in HR-Positive, HER2-Negative Breast Cancer
03/20/2026
Sarah Premji, MD
Sarah Premji, MD, discusses whether emerging oral SERDs differ in HR-positive, HER2-negative breast cancer.
Sarah Premji, MD, discusses whether emerging oral SERDs differ in HR-positive, HER2-negative breast cancer.
Sarah Premji, MD, discusses...
03/20/2026
Oncology
Sara Tolaney, MD
Videos
Sacituzumab Govitecan Plus Pembrolizumab in PD-L1-Positive Triple-Negative Breast Cancer
02/18/2026
Sara Tolaney, MD
Sara Tolaney, MD, discusses results from the phase 3 ASCENT-04 trial, assessing sacituzumab govitecan plus pembrolizumab in PD-L1–positive, locally advanced unresectable or metastatic triple-negative breast cancer.
Sara Tolaney, MD, discusses results from the phase 3 ASCENT-04 trial, assessing sacituzumab govitecan plus pembrolizumab in PD-L1–positive, locally advanced unresectable or metastatic triple-negative breast cancer.
Sara Tolaney, MD, discusses...
02/18/2026
Oncology
Sami Diab, MD
Videos
Updated NCCN Guidelines Strengthen Support for Breast Cancer Index® in Extended Endocrine Therapy Decision-Making
01/23/2026
Sami Diab, MD
Sami Diab, MD, discusses recent updates to the NCCN Clinical Practice Guidelines in Oncology for Breast Cancer, which reinforces the Breast Cancer Index® as the only genomic test predictive of benefit from extended endocrine therapy in...
Sami Diab, MD, discusses recent updates to the NCCN Clinical Practice Guidelines in Oncology for Breast Cancer, which reinforces the Breast Cancer Index® as the only genomic test predictive of benefit from extended endocrine therapy in...
Sami Diab, MD, discusses recent...
01/23/2026
Oncology
Kelly McCann, MD, PhD, UCLA
Videos
Sequencing Antibody-Drug Conjugates Among Patients With Breast Cancer
09/18/2025
Kelly McCann, MD, PhD
Kelly McCann, MD, PhD, discusses the sequencing of antibody-drug conjugates for patients with breast cancer.
Kelly McCann, MD, PhD, discusses the sequencing of antibody-drug conjugates for patients with breast cancer.
Kelly McCann, MD, PhD, discusses...
09/18/2025
Oncology
Heather Moore, CPP, PharmD, Duke Cancer Center
Videos
Managing Adverse Events for Patients With Breast Cancer
09/17/2025
Heather Moore, PharmD
Heather Moore, CPP, PharmD, discusses the management of adverse events for patients with breast cancer.
Heather Moore, CPP, PharmD, discusses the management of adverse events for patients with breast cancer.
Heather Moore, CPP, PharmD,...
09/17/2025
Oncology
Seth Wander, MD, PhD; Rachel Abelman, MD, Massachusetts General Brigham Cancer Center
Videos
Omitting Carboplatin from Neoadjuvant Regimen for Patients With HER2-Positive Early Breast Cancer
07/31/2025
Seth Wander, MD
Rachel Abelman, MD, and Seth Wander, MD, PhD, Massachusetts General Brigham Cancer Center, discuss the phase 3 neoCARHP study.
Rachel Abelman, MD, and Seth Wander, MD, PhD, Massachusetts General Brigham Cancer Center, discuss the phase 3 neoCARHP study.
Rachel Abelman, MD, and Seth...
07/31/2025
Oncology
Kelly McCann, Md, PhD, University of California, Los Angeles
Videos
Improving Abemaciclib Tolerability With a Dose Escalation Strategy for Early Stage HR-Positive, HER2-Negative Breast Cancer
06/11/2025
Kelly McCann, MD, PhD
Kelly McCann, MD, PhD, shares insights on the results from the phase 2 TRADE study which evaluated the use of a dose escalation strategy for adjuvant abemaciclib to improve tolerability for patients with early-stage high-risk HR-positive,...
Kelly McCann, MD, PhD, shares insights on the results from the phase 2 TRADE study which evaluated the use of a dose escalation strategy for adjuvant abemaciclib to improve tolerability for patients with early-stage high-risk HR-positive,...
Kelly McCann, MD, PhD, shares...
06/11/2025
Oncology

Recent News

News
National Analysis Provides Greater Insights in HER2-Low Metastatic Breast Cancer
09/29/2021
Findings from a national retrospective analysis of patients with HER2-low metastatic breast cancer were presented at the virtual 2021 ESMO Congress to exhibit distinct clinical outcomes.
Findings from a national retrospective analysis of patients with HER2-low metastatic breast cancer were presented at the virtual 2021 ESMO Congress to exhibit distinct clinical outcomes.
Findings from a national...
09/29/2021
Oncology
News
Detalimogene Voraplasmid Shows Promise in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
05/22/2026
Emily Estrada
Interim results from cohort 1 of the phase 2 LEGEND study demonstrated that detalimogene voraplasmid showed encouraging efficacy and safety in Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer.
Interim results from cohort 1 of the phase 2 LEGEND study demonstrated that detalimogene voraplasmid showed encouraging efficacy and safety in Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer.
Interim results from cohort 1 of...
05/22/2026
Oncology
News
Extended Pelvic Lymph Node Dissection Shows Selective Benefit in Patients With Prostate Cancer
05/22/2026
Emily Estrada
Long-term results from a phase 3 trial demonstrated that extended pelvic lymph node dissection did not improve survival outcomes compared with limited pelvic lymph node dissection in patients with intermediate- or high-risk prostate cancer...
Long-term results from a phase 3 trial demonstrated that extended pelvic lymph node dissection did not improve survival outcomes compared with limited pelvic lymph node dissection in patients with intermediate- or high-risk prostate cancer...
Long-term results from a phase 3...
05/22/2026
Oncology
FDA Approval
FDA Approves Datopotamab Deruxtecan for Patients With Triple-Negative Breast Cancer
05/22/2026
Emily Estrada
Based on results from the TROPION-Breast02 trial, the FDA has approved datopotamab deruxtecan for patients with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1 or PD-L1 inhibitor therapy.
Based on results from the TROPION-Breast02 trial, the FDA has approved datopotamab deruxtecan for patients with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1 or PD-L1 inhibitor therapy.
Based on results from the...
05/22/2026
Oncology
News
Ipatasertib Plus Fulvestrant and Palbociclib Shows Strong Preliminary Activity in HR-Positive, HER2-Negative Breast Cancer
05/21/2026
Stephanie Holland
Clinical Summary Design/Population: The phase 1b TAKTIC trial evaluated ipatasertib plus endocrine therapy with or without palbociclib in heavily pretreated patients with HR-positive, HER2-negative metastatic breast cancer.  Key...
Clinical Summary Design/Population: The phase 1b TAKTIC trial evaluated ipatasertib plus endocrine therapy with or without palbociclib in heavily pretreated patients with HR-positive, HER2-negative metastatic breast cancer.  Key...
Clinical...
05/21/2026
Oncology
News
Lenalidomide Plus Rituximab Maintains Survival Benefit in R/R Indolent Non-Hodgkin Lymphomas
05/21/2026
Stephanie Holland
Long-term follow-up results from the phase 3 AUGMENT trial show lenalidomide plus rituximab sustained survival benefit in R/R indolent non-Hodgkin lymphomas.
Long-term follow-up results from the phase 3 AUGMENT trial show lenalidomide plus rituximab sustained survival benefit in R/R indolent non-Hodgkin lymphomas.
Long-term follow-up results from...
05/21/2026
Oncology
News
Pembrolizumab Plus BCG Shows Bladder-Preserving Potential in Non-Muscle Invasive Bladder Cancer
05/20/2026
Stephanie Holland
Results from a phase 2 trial demonstrated that pembrolizumab plus bacillus Calmette-Guérin (BCG) demonstrated encouraging bladder-preserving activity in very high-risk non-muscle-invasive bladder cancer.
Results from a phase 2 trial demonstrated that pembrolizumab plus bacillus Calmette-Guérin (BCG) demonstrated encouraging bladder-preserving activity in very high-risk non-muscle-invasive bladder cancer.
Results from a phase 2 trial...
05/20/2026
Oncology
News
Aglatimagene Improves Disease-Free Survival in Patients With Localized Prostate Cancer
05/20/2026
Stephanie Holland
Results from a phase 3 trial demonstrated that aglatimagene improved prostate cancer-specific survival when added to standard external beam radiotherapy with or without androgen deprivation therapy in localized prostate cancer.
Results from a phase 3 trial demonstrated that aglatimagene improved prostate cancer-specific survival when added to standard external beam radiotherapy with or without androgen deprivation therapy in localized prostate cancer.
Results from a phase 3 trial...
05/20/2026
Oncology
News
Tiragolumab Plus Atezolizumab and Chemotherapy in Extensive-Stage Small Cell Lung Cancer
05/19/2026
Emily Estrada
Results from the phase 3 SKYSCRAPER-02C trial demonstrated that adding tiragolumab to atezolizumab plus chemotherapy did not significantly improve survival in treatment-naïve patients with extensive-stage small cell lung cancer.
Results from the phase 3 SKYSCRAPER-02C trial demonstrated that adding tiragolumab to atezolizumab plus chemotherapy did not significantly improve survival in treatment-naïve patients with extensive-stage small cell lung cancer.
Results from the phase 3...
05/19/2026
Oncology
News
Postsurgical ctDNA is Associated With Recurrence in Metastatic Colorectal Cancer
05/19/2026
Emily Estrada
Results from a prospective study suggest that ctDNA dynamics may help stratify recurrence risk in patients with liver-limited metastatic colorectal cancer undergoing liver resection after upfront chemotherapy.
Results from a prospective study suggest that ctDNA dynamics may help stratify recurrence risk in patients with liver-limited metastatic colorectal cancer undergoing liver resection after upfront chemotherapy.
Results from a prospective study...
05/19/2026
Oncology
News
Durvalumab Plus BCG Delays High-Risk Recurrence in Non-Muscle-Invasive Bladder Cancer
05/19/2026
Stephanie Holland
Updated results from the POTOMAC trial demonstrate that durvalumab plus Bacillus Calmetter-Guerin (BCG) induction and maintenance reduced recurrence-related outcomes in patients with high-risk non-muscle-invasive bladder cancer.
Updated results from the POTOMAC trial demonstrate that durvalumab plus Bacillus Calmetter-Guerin (BCG) induction and maintenance reduced recurrence-related outcomes in patients with high-risk non-muscle-invasive bladder cancer.
Updated results from the POTOMAC...
05/19/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use